Medicare National Coverage Determination: Beta Amyloid Positron Emission Tomography In Dementia & Neurodegenerative Disease

On October 13, 2023, the The Centers for Medicare & Medicaid Services (CMS) published this decision memo Medicare national coverage determination (NCD) regarding beta amyloid positron emission tomography (PET) in dementia and neurodegenerative disease. This decision memo removes tha NCD, ends coverage with evidence development (CED) for pPET beta amyloid imaging, and permits Medicare coverage determinations for PET beta amyloid imaging to be made by the Medicare Administrative Contractors (MACs) under § 1862(a)(1)(A) of the Social Security Act (the Act . . .